Mexico Faces Medicine Shortages as Suppliers Fail to Deliver
Table of Contents
Mexico City – The government of President Claudia Sheinbaum is attributing ongoing medicine shortages in the public health sector to failures by suppliers to fulfill contracted deliveries. Officials presented a list of companies failing to meet their obligations during a recent press conference,highlighting a critically importent disruption to the supply of essential medications,particularly for cancer treatment.
Government Accusations and Supplier Non-Compliance
Eduardo Clark, Undersecretary of integration and Progress of the Health Sector, detailed the issue during the daily “mañanera” press briefing. He stated that numerous companies, both domestic and international, have not delivered medications despite having won contracts months ago. https://www.milenio.com/politica/claudia-sheinbaum-gobierno-medicamentos-faltantes-proveedores
“Companies, some nationals, many foreigners who acquired commitments when we tendered, to date they have not fulfilled that commitment,” Clark explained.
Current Supply Levels & Areas of Concern
As of September 20, the government reported varying levels of medicine supply across key institutions:
* IMSS (Mexican social Security institute): 97% supply
* IMSS-Bienestar (Well-being Institute): 92% supply
* ISSSTE (Social Security Institute for Workers of the State): 97% supply
Despite these figures, officials emphasized the need for continued pressure on pharmaceutical companies to deliver outstanding orders. Cancer medications remain a particularly critical area of concern. Clark noted recent improvements in industry response for cancer treatments but identified ongoing issues with specific suppliers.
Companies Named in Supply Failures
The government specifically called out several companies for significant shortfalls:
* Bioxintegral Servicios: Failed to deliver any of the medications contracted.
* Pharmaceutical Products: Has not delivered 88.6% of requested medications.
* Zurich Pharma: Is missing the delivery of 56,000 medications, primarily oncological drugs.
Clark stressed the severe impact of these failures, stating that a shortfall of 56,000 oncology medications by a single company jeopardizes the health of Mexican patients. He urged companies to prioritize their commitments to the country’s healthcare system. https://www.elfinanciero.com.mx/salud/2023/09/26/gobierno-de-sheinbaum-acusa-a-empresas-de-no-cumplir-con-entrega-de-medicamentos/
Looking ahead
The Mexican government is actively working to resolve the medicine supply issues by holding suppliers accountable and seeking alternative sources. The situation highlights the vulnerabilities in the pharmaceutical supply chain and the importance of reliable partnerships to ensure access to essential medications for the Mexican population. Further updates are expected as the government continues to negotiate with suppliers and monitor delivery progress.
Key Takeaways:
* The Mexican government attributes medicine shortages to supplier non-compliance with contracts.
* Shortages are impacting the supply of essential medications, particularly for cancer treatment.
* Several companies have been publicly identified for significant delivery failures.
* The government is actively working to resolve the issue and ensure access to medications for its citizens.